Recently, nucleotide‐binding, leucine‐rich repeat and pyrin domain‐containing protein 3 (NLRP3) inflammasome has been suggested as a new therapeutic target for CM [23, 24]. Here, NLRP3 is linked to cutaneous mastocytosis.